SESEN BIO, INC. may be overvalued. Its Value Score of F indicates it would be a bad pick for value investors. The financial health and growth prospects of SESN, demonstrate its potential to underperform the market.
Will SESN bio stock go up?
Will Sesen Bio stock price grow / rise / go up? Yes. The SESN stock price can go up from 0.733 USD to 0.982 USD in one year.
Is Baudax bio stock a buy?
Is Baudax Bio a buy right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Baudax Bio in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Baudax Bio stock.
Is SESN a good buy?
Out of 2 analysts, 1 (50%) are recommending SESN as a Strong Buy, 0 (0%) are recommending SESN as a Buy, 1 (50%) are recommending SESN as a Hold, 0 (0%) are recommending SESN as a Sell, and 0 (0%) are recommending SESN as a Strong Sell. What is SESN's earnings growth forecast for 2022-2024?
Who owns Sesen Bio?
Stockholder Stake Total value ($)
---------------------------- ----- ---------------
The Vanguard Group, Inc. 4.91% 7,977,272
SSgA Funds Management, Inc. 2.01% 3,269,827
Two Sigma Investments LP 1.39% 2,260,315
Geode Capital Management LLC 1.31% 2,136,107
Will Sesen Bio get FDA approval?
After completing its BLA in (in the US) Sesen expected the FDA to accept it by Q1 2021. It was later to be approved by that would make the product available by Q4 2021.16 Nov 2021
What does Sesen Bio do?
At Sesen Bio, we are committed to saving and improving the lives of patients with cancer. We are a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer.
Is Sesen Bio a good stock to buy?
Is Sesen Bio a buy right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sesen Bio in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Sesen Bio stock.
Will Vicinium get approved?
The FDA has issued a complete response letter to Sesen Bio, denying the approval of the Biologics License Application for Vicinium for the treatment of BCG-unresponsive non-muscle invasive bladder cancer.16 Aug 2021